TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less.....

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Willsgarden who wrote (57479)	2/5/2007 4:29:24 PM
From: MJ	Read Replies (1) of 59879

Bill This is the 2/05/07 news. GNBT is much more than it seems at first blush. See the SI quote for full article. "Volunteers Selected for Human Clinical Trial of Generex Biotechnology's Synthetic Avian Influenza Vaccine Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that 50 volunteers have been selected and final preparations made for initiation of human clinical trials of the synthetic avian influenza vaccine under development by its wholly owned subsidiary, Antigen Express, Inc. The Company previously entered into an agreement with the Lebanese-Canadian Hospital in Beirut, Lebanon to conduct the Phase I trial. An additional 70 prospective volunteers are presently being screened by the Hospital. An aggregate of 160 patients are expected to participate in the trial." Going to stay with this for awhile. mj

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next